HomeCompareABSCF vs EPRT

ABSCF vs EPRT: Dividend Comparison 2026

ABSCF yields 137.93% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABSCF wins by $16.39M in total portfolio value
10 years
ABSCF
ABSCF
● Live price
137.93%
Share price
$1.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16.45M
Annual income
$6,780,916.45
Full ABSCF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — ABSCF vs EPRT

📍 ABSCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABSCFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABSCF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABSCF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABSCF
Annual income on $10K today (after 15% tax)
$11,724.14/yr
After 10yr DRIP, annual income (after tax)
$5,763,778.98/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, ABSCF beats the other by $5,752,583.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABSCF + EPRT for your $10,000?

ABSCF: 50%EPRT: 50%
100% EPRT50/50100% ABSCF
Portfolio after 10yr
$8.26M
Annual income
$3,397,043.65/yr
Blended yield
41.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ABSCF
No analyst data
Altman Z
-1.3
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABSCF buys
0
EPRT buys
0
No recent congressional trades found for ABSCF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABSCFEPRT
Forward yield137.93%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$16.45M$64.3K
Annual income after 10y$6,780,916.45$13,170.85
Total dividends collected$15.13M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ABSCF vs EPRT ($10,000, DRIP)

YearABSCF PortfolioABSCF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$24,493$13,793.10$11,212$512.01+$13.3KABSCF
2$57,781$31,573.45$12,689$692.09+$45.1KABSCF
3$131,437$69,611.34$14,521$944.30+$116.9KABSCF
4$288,626$147,988.71$16,841$1,302.88+$271.8KABSCF
5$612,543$303,712.69$19,841$1,821.64+$592.7KABSCF
6$1,257,814$602,392.61$23,818$2,587.47+$1.23MABSCF
7$2,501,908$1,156,047.28$29,230$3,744.65+$2.47MABSCF
8$4,826,093$2,149,051.62$36,816$5,540.38+$4.79MABSCF
9$9,038,168$3,874,248.32$47,806$8,413.17+$8.99MABSCF
10$16,451,756$6,780,916.45$64,324$13,170.85+$16.39MABSCF

ABSCF vs EPRT: Complete Analysis 2026

ABSCFStock

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Full ABSCF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ABSCF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABSCF vs SCHDABSCF vs JEPIABSCF vs OABSCF vs KOABSCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.